RxDoctor Payments Data

George Tompkins, DO

Family Medicine · van Buren, ARNPI 1164418679

Payments from drug & device makers

$1,277in general payments, 2019–2025

Across 55 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$513
  • AstraZeneca$246
  • Radius Health, Inc.$153
  • AbbVie$128
  • Eisai Inc.$53
  • Pfizer$41
  • plus $144 from 7 others

What the payments were for

  • Food & beverage$1,24798%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,277 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$30,038
Medicare patients
41
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter257$198,653
OzempicSemaglutide83$101,162
MounjaroTirzepatide40$67,960
EliquisApixaban25$20,157
XareltoRivaroxaban26$18,750
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen495$14,943
Combivent RespimatIpratropium/Albuterol Sulfate18$11,333
QuviviqDaridorexant Hcl14$9,811
LinzessLinaclotide18$9,505
JardianceEmpagliflozin15$9,163
TradjentaLinagliptin13$6,742
Albuterol Sulfate HfaAlbuterol Sulfate274$6,689
Spiriva RespimatTiotropium Bromide12$6,352
Breo ElliptaFluticasone/Vilanterol13$5,247
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$513$203,900270 claims
Boehringer IngelheimCombivent Respimat, Jardiance, Tradjenta, Spiriva Respimat$14$33,59058 claims
PfizerEliquis$41$20,15725 claims
Johnson & JohnsonXarelto$18$18,75026 claims
AbbVieLinzess$128$9,50518 claims
AstraZenecaSymbicort$246$3,60616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in van Buren

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →